Focal Segmental Glomerulosclerosis Drugs Global Market Report 2024

The global focal segmental glomerulosclerosis drugs market has grown strongly in recent years. It will grow from $14.43 billion in 2023 to $15.77 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increasing disease prevalence, growing demand for new treatments, growing interest from pharmaceutical sector, increasing government support.

The global focal segmental glomerulosclerosis drugs market is expected to see strong growth in the next few years. It will grow to $22.41 billion in 2028 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to research and development expenditure, rising healthcare expenditure, growing awareness and diagnosis, aging population, government initiatives and funding. Major trends in the forecast period include technological advancements in drug discovery and development, expanding clinical trials pipeline, improved reimbursement for focal segmental glomerulosclerosis drugs treatments, expansion of corporate research facilities.

The increasing incidence of kidney infections is poised to drive the expansion of the focal segmental glomerulosclerosis (FSGS) drugs market in the foreseeable future. Kidney infections, also known as pyelonephritis, represent a severe form of urinary tract infection (UTI) that affects one or both kidneys. Focal segmental glomerulosclerosis (FSGS) drugs, designed for the treatment of kidney diseases, offer numerous advantages in managing the condition and enhancing kidney function. They achieve this by reducing proteinuria, slowing the progression of kidney damage, and ultimately improving the quality of life for patients suffering from kidney diseases. For example, as of July 2022, data from the Centers for Disease Control and Prevention, a division of the US Department of Health and Human Services, revealed that approximately 15% of the US population, equivalent to 37 million individuals, were afflicted by kidney disease. In 2021, the prevalence was 12% among individuals aged 45-64 and 6% among those between 18 and 44. Consequently, the increasing occurrence of kidney infections serves as a driving force behind the growth of the focal segmental glomerulosclerosis (FSGS) market.

The growth of the focal segmental glomerulosclerosis (FSGS) drugs market is expected to be propelled by the increase in healthcare expenditure. Healthcare expenditure encompasses the total amount of money invested in healthcare services and associated products and activities within a specific healthcare system or economy during a specified period. The rising healthcare expenditures play a crucial role in the development and availability of drugs for focal segmental glomerulosclerosis (FSGS). They lead to greater research funding and increased clinical trials, ultimately contributing to improved drug development. For instance, a report from the UK's Office for National Statistics revealed that healthcare spending in the UK saw a 9.4% increase in nominal terms and a 9.7% increase in real terms between 2020 and 2021. The UK's total healthcare expenditure in 2021 amounted to $367.25 billion (£280.7 billion), with pharmaceutical expenditure reaching $51.84 billion (£39.6 billion) in the same year. Furthermore, preventive care spending more than doubled from 2020, reaching $45.93 billion (£35.1 billion) in 2021. Hence, the surge in healthcare expenditures is a driving force behind the growth of the focal segmental glomerulosclerosis (FSGS) drugs market.

The high cost of treatment in the focal segmental glomerulosclerosis (FSGS) market is expected to impede its growth during the forecast period. FSGS is a rare and severe kidney disorder that can ultimately lead to kidney failure. Patients suffering from FSGS often necessitate comprehensive and costly medical care, including hospitalization, dialysis, potential kidney transplantation, intensive care, and specialized diagnostic tests. For instance, the American Hospital Association, a professional organization in the United States, reported a 2.1% increase in hospitalization prices over the year leading up to February 2022. As a result, the substantial expense associated with treatment is acting as a deterrent to the growth of the focal segmental glomerulosclerosis (FSGS) market in the foreseeable future.

Prominent companies in the focal segmental glomerulosclerosis (FSGS) market are increasingly directing their efforts toward product development and innovation to deliver dependable solutions to their clientele and bolster their market standing. As an example, in February 2023, Travere Therapeutics, a biopharmaceutical firm headquartered in the United States, introduced FILSPARI for focal segmental glomerulosclerosis (FSGS), an FDA-approved oral medication. FILSPARI is designed to treat IgA nephropathy (IgAN) and represents the first non-immunosuppressive therapy aimed at reducing proteinuria in IgAN, a rare kidney disease. Furthermore, FILSPARI has received orphan drug designation in both the United States and Europe for the treatment of IgAN and focal segmental glomerulosclerosis (FSGS).

In July 2021, AstraZeneca PLC, a pharmaceutical and biotechnology company headquartered in the United Kingdom, completed the acquisition of Alexion Pharmaceuticals for a total of $13.3 billion. This strategic acquisition enhances AstraZeneca's product portfolio, particularly in the manufacturing of drugs tailored for rare diseases that have limited approved treatment options. Additionally, it bolsters their research and development investments across various therapeutic areas, including oncology, cardiology, renal, respiratory, and immunology. Alexion Pharmaceuticals, a pharmaceutical firm based in the United States, specializes in the production of medications for kidney diseases, including focal segmental glomerulosclerosis (FSGS).

Major players in the focal segmental glomerulosclerosis drugs market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Fresenius Kabi Ltd., GSK PLC, Medtronic Plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., B. Braun Melsungen AG, Hikma Pharmaceuticals PLC, Alexion Pharmaceuticals, Wockhardt, Travere Therapeutics, Aurinia Pharmaceuticals Inc., Omeros Corporation, Dimerix Ltd., Goldfinch Bio.

North America was the largest region in the focal segmental glomerulosclerosis drugs market in 2023. The regions covered in the focal segmental glomerulosclerosis (FSGS) drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the focal segmental glomerulosclerosis (FSGS) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The primary focal segmental glomerulosclerosis drugs include losmapimod, SHP-627, sparsentan, tm-5484, and others. Losmapimod is an investigational drug belonging to the class of p38 mitogen-activated protein kinase (MAPK) inhibitors. Treatment options encompass corticosteroids, immunosuppressive drugs, ACE inhibitors, AR blockers, diuretics, and more, which can be administered through various routes, including oral and parenteral. These medications serve various end-users, such as hospitals, homecare services, specialty clinics, and more.

This report provides focal segmental glomerulosclerosis drugs market statistics, including focal segmental glomerulosclerosis drugs industry global market size, regional shares, competitors with a focal segmental glomerulosclerosis drugs market share, detailed focal segmental glomerulosclerosis drugs market segments, market trends and opportunities and any further data you may need to thrive in the focal segmental glomerulosclerosis drugs industry. This focal segmental glomerulosclerosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The focal segmental glomerulosclerosis (FSGS) drugs market consists of sales of rituximab, statins, and cyclophosphamide. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.